Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Biswas, Ghanshyam; Pandey, Avinash Kumar; Ghadyalpatil, N.; Lokeshwar, Nilesh; Thomas, Boben; Ramesh, Anita; Arora, Yogesh; Dodagoudar, Chandragouda; Naik, Vibhavari; Joshi, Anuradha Rajiv; Ghosh, Indranil; Roy, Rakesh; Medhi, Kunjahari; Singh, Tejinder P.; Satya, Palanki Dattatreya; Hingmire, Sachin; Parikh, Purvish M.

doi:10.4103/sajc.sajc_246_19

Cited by 2 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, it is well established that with the use of FCM in the appropriate dose at least once, we can provide our cancer patients with a safe and effective method to increase their Hb levels, avoid the risk of blood transfusion requirements, and enhance QoL. 6 14 22 30 42 48…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Parikh,

Aggarwal,

Biswas

et al. 2023

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

Cancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- and middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, and difficulty in having easily accessible affordable healthcare. Hence, we fulfilled the need of guidelines for LMIC. A group of subject experts were put together, given background literature, met in a face-to-face discussion, voted using Delphi process, and finally agreed on the contents of this guideline document. As many as 50% of cancer patients will have significant anemia (hemoglobin < 10 g/dL) at initial diagnosis. It is most commonly seen with gastrointestinal malignancies, head and neck cancers, and acute leukemias. The hemoglobin falls further after initiation of cancer directed therapy, due to chemotherapy itself or heightened nutritional deficiency. Its evaluation should include tests for complete blood count, red blood cell morphology, reticulocyte count, Coombs test, and levels of vitamin B12 and folic acid. Iron status should be monitored using test to measure serum iron, total iron binding capacity, transferring saturation, and serum ferritin levels. A minimum of 50% of cancer patients with anemia require iron supplements. The preferred mode of therapy is with intravenous (IV) iron using ferric carboxymaltose (FCM). Most patients respond satisfactorily to single dose of 1000 mg. It is also safe and does not require use of a test dose. Significant anemia is found in at least half of all cancer patients in India, South Asian Association for Regional Cooperation region, and other LMIC countries. Its awareness among healthcare professionals will prevent it from remaining undiagnosed (in up to 70% of all cancer patients) and adversely affecting OS and QoL. The benefits of treating them with IV iron therapy are quick replenishment of iron stores, hemoglobin returning to normal, better QoL, and avoiding risk of infections/reactions with blood transfusions. Many publications have proven the value of single-dose FCM in such clinical situations. CAA has been proven to be an independent prognostic factor that adversely affects both QoL and OS in cancer patients. Use of FCM as single IV dose of 1000 mg is safe and effective in the majority of patients with CAA.

show abstract

Section: Discussionmentioning

confidence: 99%

“…chemotherapy and/or radiation therapy). 6 7 Cancer by itself also leads to anemia of chronic diseases (just like that seen with others chronic inflammatory diseases and renal failure). 8 CAA is proportional to the tumor burden/stage of cancer.…”

Section: Introductionmentioning

confidence: 98%

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Parikh,

Aggarwal,

Biswas

et al. 2023

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…chemotherapy and/or radiation therapy). 6,7 Cancer by itself also leads to anemia of chronic diseases (just like that seen with others chronic inflammatory diseases and renal failure). 8 CAA is proportional to the tumor burden/stage of cancer.…”

Section: Introductionmentioning

confidence: 94%

Untitled

2023

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Cited by 2 publications

References 27 publications

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Untitled

Contact Info

Product

Resources

About